nuantic offers AI-guided lead optimization to biotech and pharma customers developing protein- and peptide-based therapeutics. We're able to optimize affinity, developability and aspects of immunogenicity with outstanding success rates with 10x less effort as compared to traditional methods.

FoRx Therapeutics is a clinical-stage company that develops next-generation small molecule therapeutics targeting DNA Replication Stress pathways for anti-cancer therapy. The lead program is a highly potent and selective PARG inhibitor, FORX-428, which  moved into clinical Phase 1 in H2 2025.

arcoris bio develops next-generation technologies for biomarker detection in research and diagnostics. Its flagship MUSE® platform provides universal, programmable signal amplification to enable highly sensitive and multiplex assays that drive the future of digital pathology.